NRIX (Nurix Therapeutics) Beginning Cash Position: $72.16 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
61 GF Score
Price $25.22
GF Value $6.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Beginning Cash Position?

Nurix Therapeutics NRIX +0.36% 61 Beginning Cash Position is $72.16 Mil as of May. 2026. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Nurix Therapeutics's Beginning Cash Position for the quarter that ended in May. 2026 was $72.16 Mil.

Nurix Therapeutics's quarterly Beginning Cash Position increased from Nov. 2025 ($79.41 Mil) to Feb. 2026 ($247.93 Mil) but then declined from Feb. 2026 ($247.93 Mil) to May. 2026 ($72.16 Mil).

Nurix Therapeutics's annual Beginning Cash Position declined from Nov. 2023 ($65.38 Mil) to Nov. 2024 ($55.53 Mil) but then increased from Nov. 2024 ($55.53 Mil) to Nov. 2025 ($110.90 Mil).

Nurix Therapeutics Beginning Cash Position Related Terms

Nurix Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Nurix Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics Beginning Cash Position Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Beginning Cash Position
Get a 7-Day Free Trial 119.53 80.79 65.38 55.53 110.90

Nurix Therapeutics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.82 85.16 79.41 247.93 72.16
NRIX
61GF Score
Nurix Therapeutics Inc NRIX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nurix Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $72.16 Mil mean?
Nurix Therapeutics (NRIX) has a Beginning Cash Position of $72.16 Mil as of May. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nurix Therapeutics and its competitors.
Is Nurix Therapeutics' Beginning Cash Position too high?
Nurix Therapeutics' current Beginning Cash Position is $72.16 Mil. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Beginning Cash Position compare to PHVS and NKTR?
Nurix Therapeutics' Beginning Cash Position of $72.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nurix Therapeutics and its competitors. Nurix Therapeutics's current Beginning Cash Position is $72.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.40, compared to a current price of $25.22 — trading 294.1% above its estimated fair value. The current Beginning Cash Position is $72.16 Mil. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Beginning Cash Position is $72.16 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $25.22 is trading 294.1% above its estimated GF Value™ of $6.40. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Beginning Cash Position: $72.16 Mil
  • GF Value™: $6.40 vs. price of $25.22 (294.1% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score

Get the complete analysis for NRIX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.22
Price
$6.40
GF Value